» Articles » PMID: 21679416

Retention in an Antiretroviral Therapy Programme During an Era of Decreasing Drug Cost in Limbe, Cameroon

Overview
Journal J Int AIDS Soc
Date 2011 Jun 18
PMID 21679416
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In 2002, Cameroon initiated scale up of antiretroviral therapy (ART); on 1 October 2004, a substantial reduction in ART cost occurred. We assessed the impact of this event and other factors on enrolment and retention in care among HIV-infected patients initiating ART from February 2002 to December 2005 at the single ART clinic serving the Southwest Region in Limbe, Cameroon.

Methods: We retrospectively analyzed clinical and pharmacy payment records of HIV-infected patients initiating ART according to national guidelines. We compared two cohorts of patients, enrolled before and after 1 October 2004, to determine if price reduction was associated with enhanced enrolment. We assessed factors associated with retention and survival by Cox proportional hazards models. Retention in care implied patients who had contact with the healthcare system as of 31 December 2005 (including those who were transferred to continue care in other ART centres), although these patients may have interrupted therapy at some time. A patient who was not retained in care may have dropped out (lost to follow up) or died.

Results: Mean enrolment rates for 2920 patients who initiated ART before and after the price reduction were 46.5 and 95.5 persons/month, respectively (p < 0.001). The probabilities of remaining alive and in care were 0.66 (95% CI 0.64-0.68) at six months, 0.58 (95% CI 0.56-0.60) at one year, 0.47 (95% CI 0.45-0.49) at two years and 0.35 (95% CI 0.32-0.38) at three years; they were not significantly different between the two cohorts of patients enrolled before and after the price reduction over the first 15 months of comparable follow up (hazard ratio 1.1; 95% CI 0.9-1.2, p = 0.27). In multivariable analysis using multiple imputations to compensate for missing values, factors associated with dropping out of care or dying were male gender (HR 1.33 [1.18-1.50], p = 0.003), treatment paid by self, family or partly by other (HR 3.05 [1.99-4.67], p < 0.001), and, compared with residents of Limbe, living more than 150 km from Limbe (HR 1.41 [1.18-1.69], p < 0.001), or being residents of Douala (HR 1.51 [1.16-1.98], p < 0.001).

Conclusions: Reducing the cost of ART increased enrolment of clients in the programme, but did not change retention in care. In a system where most clients pay for ART, an accessible clinic location may be more important than the cost of medication for retention in care. Decentralizing ART clinics might improve retention and survival among patients on ART.

Citing Articles

Interventions to improve early retention of patients in antiretroviral therapy programmes in sub-Saharan Africa: A systematic review.

Muhula S, Gachohi J, Kombe Y, Karanja S PLoS One. 2022; 17(2):e0263663.

PMID: 35139118 PMC: 8827476. DOI: 10.1371/journal.pone.0263663.


The impact of user fees on uptake of HIV services and adherence to HIV treatment: Findings from a large HIV program in Nigeria.

Ahonkhai A, Regan S, Idigbe I, Adeniyi O, Aliyu M, Okonkwo P PLoS One. 2020; 15(10):e0238720.

PMID: 33031440 PMC: 7544141. DOI: 10.1371/journal.pone.0238720.


Effect of PEPFAR funding policy change on HIV service delivery in a large HIV care and treatment network in Nigeria.

Banigbe B, Audet C, Okonkwo P, Arije O, Bassi E, Clouse K PLoS One. 2019; 14(9):e0221809.

PMID: 31553735 PMC: 6760763. DOI: 10.1371/journal.pone.0221809.


Improving retention in HIV care among adolescents and adults in low- and middle-income countries: A systematic review of the literature.

Murray K, Dulli L, Ridgeway K, Santo L, Darrow de Mora D, Olsen P PLoS One. 2017; 12(9):e0184879.

PMID: 28961253 PMC: 5621671. DOI: 10.1371/journal.pone.0184879.


Retention of Adult Patients on Antiretroviral Therapy in Low- and Middle-Income Countries: Systematic Review and Meta-analysis 2008-2013.

Fox M, Rosen S J Acquir Immune Defic Syndr. 2015; 69(1):98-108.

PMID: 25942461 PMC: 4422218. DOI: 10.1097/QAI.0000000000000553.


References
1.
Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G . Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005; 353(22):2325-34. DOI: 10.1056/NEJMoa051908. View

2.
Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B . Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS. 2003; 17 Suppl 3:S5-15. DOI: 10.1097/00002030-200317003-00002. View

3.
Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View

4.
Weidle P, Wamai N, Solberg P, Liechty C, Sendagala S, Were W . Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet. 2006; 368(9547):1587-94. DOI: 10.1016/S0140-6736(06)69118-6. View

5.
Davies G, Koenig L, Stratford D, Palmore M, Bush T, Golde M . Overview and implementation of an intervention to prevent adherence failure among HIV-infected adults initiating antiretroviral therapy: lessons learned from Project HEART. AIDS Care. 2006; 18(8):895-903. DOI: 10.1080/09540120500329556. View